Edition:
United States

Gilead Sciences Inc (GILD.O)

GILD.O on Nasdaq

81.05USD
26 Jul 2016
Change (% chg)

-- (--)
Prev Close
$81.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
10,230,217
52-wk High
$120.37
52-wk Low
$77.92

Summary

Name Age Since Current Position

John Martin

64 2016 Executive Chairman of the Board

John Milligan

54 2016 Chief Executive Officer, Director

Robin Washington

53 2014 Chief Financial Officer, Executive Vice President

Kevin Young

55 2016 Chief Operating Officer

Norbert Bischofberger

60 2007 Executive Vice President - Research and Development, Chief Scientific Officer

Kathleen Watson

2016 Executive Vice President - Human Resources

Gregg Alton

50 2009 Executive Vice President - Corporate and Medical Affairs

Martin Silverstein

48 2016 Executive Vice President - Strategy

John Cogan

68 2013 Lead Independent Director

Kevin Lofton

61 2009 Independent Director

John Madigan

78 2005 Independent Director

Nicholas Moore

74 2004 Independent Director

Richard Whitley

70 2008 Independent Director

Gayle Wilson

73 2001 Independent Director

Per Wold-Olsen

68 2010 Independent Director

Biographies

Name Description

John Martin

Dr. John C. Martin, Ph.D., is Executive Chairman of the Board of the Company. Dr. Martin has served as Gilead’s Executive Chairman since March 2016 and previously served as Chief Executive Officer since 1996. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb Company and Syntex Corporation. Dr. Martin holds a Ph.D. in organic chemistry from the University of Chicago and an MBA in marketing from Golden Gate University. He has received the Isbell Award from the American Chemical Society and the Gertrude B. Elion Award for Scientific Excellence from the International Society for Antiviral Research. In 2008, Dr. Martin was inducted into the National Academy of Engineering of the National Academies.

John Milligan

Dr. John F. Milligan, Ph.D., is Chief Executive Officer, Director of the Company. He serves as President, Chief Operating Officer of Gilead Sciences Inc. Dr. Milligan joined Gilead in 1990 as a Research Scientist, and in 1996, he became Director of Project Management and Project Team Leader for Gilead’s collaboration with Hoffmann-La Roche Ltd on Tamiflu®. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was promoted to Chief Operating Officer in 2007 and President in 2008. Dr. Milligan is a member of the board of Biotechnology Industry Organization (BIO), the largest biotechnology industry organization, and a Trustee of Ohio Wesleyan University. Dr. Milligan received his B.A. in chemistry from Ohio Wesleyan University and his Ph.D. in biochemistry from the University of Illinois and was an American Cancer Society postdoctoral fellow at the University of California at San Francisco.

Robin Washington

Ms. Robin L. Washington is Chief Financial Officer, Executive Vice President of Gilead Sciences, Inc. Ms. Washington joined us in 2008 and oversees our global finance and information technology organizations. Prior to joining Gilead, Ms. Washington was Chief Financial Officer at Hyperion Solutions, which was acquired by Oracle Corporation in 2007. She previously served in a number of executive positions with PeopleSoft, most recently in the role of Senior Vice President and Corporate Controller. Ms. Washington is a member of the Board of Directors of Honeywell International, the board of directors of Salesforce.com and the board of visitors, Graziadio School of Business and Management, Pepperdine University. She previously served on the board of directors of Tektronix, Inc. (acquired by Danaher) and the board of directors of MIPS Technologies Inc. (acquired by Imagination). She is a certified public accountant and holds a bachelor’s degree in business administration from the University of Michigan and an MBA from Pepperdine University.

Kevin Young

Mr. Kevin B. Young, CBE, is Chief Operating Officer of Gilead Sciences, Inc., He will assume responsibility for Gilead's worldwide commercial organization, and facilities and operations. From 2004 through 2014, Mr. Young served as Gilead's Executive Vice President of Commercial Operations. Since 2014, he has held the role of senior advisor to the company. Prior to Gilead, he spent more than 20 years in the biopharmaceutical industry, first with ICI Pharmaceuticals and subsequently with Amgen. Mr. Young has undergraduate and graduate degrees in Sports Science and Exercise from Liverpool and Nottingham, England. In 2011, he was appointed a Commander of The British Empire, one of Great Britain's highest civilian honors, in recognition of his "services to the healthcare and pharmaceutical industries.

Norbert Bischofberger

Dr. Norbert W. Bischofberger, Ph.D., is Executive Vice President of Research and Development, Chief Scientific Officer of Gilead Sciences Inc. Dr. Bischofberger joined Gilead in 1990 and has served as Executive Vice President, Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech, Inc.’s DNA Synthesis group from 1986 to 1990. He received his Ph.D. in Organic Chemistry at the Eidgenossische Technische Hochschule (ETH) in Zurich, Switzerland and performed postdoctoral research in steroid chemistry at Syntex. He also performed additional research in organic chemistry and applied enzymology in Professor George Whiteside’s lab at Harvard University in Cambridge, Massachusetts.

Kathleen Watson

Ms. Kathleen Watson has been promoted as Executive Vice President - Human Resources of the Company. Ms. Watson joined Gilead in February 2003 and since that time has taken on increasing levels of responsibility and management within the HR organization. Ms. Watson was appointed Vice President of Employee Development and Rewards in 2012 and was promoted to Senior Vice President, Human Resources in 2013. Before joining Gilead, she was a manager of compensation for Applera Corporation, led the HR consulting practice for TriNet and worked as an HR business partner for DE Shaw & Co. Ms. Watson holds a degree in Psychology from the University of California at San Diego and a master's in Organizational Psychology from Columbia University.

Gregg Alton

Mr. Gregg H. Alton is Executive Vice President - Corporate and Medical Affairs of Gilead Sciences Inc. Mr. Alton joined us in 1999, and served as General Counsel from 2000 to 2009, when he was appointed to his current position. In his current role, Mr. Alton is responsible for legal affairs, government affairs, medical affairs, public affairs and emerging market activities. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for healthcare and information technology companies. Mr. Alton is a member of the boards of the AIDS Institute, the Boys and Girls Clubs of Oakland and Celladon Corporation. He is also a member of the U.S. Government’s Industry Trade Advisory Committee on Intellectual Property Rights, the advisory boards of UCSF Global Health Sciences, USC Schaeffer Center for Health Policy and Economics, Pharmozyme, Inc. and the Dean’s Advisory Council at Stanford Law School. In addition, he serves on Partners In Health’s Board of Trustees. Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley, and holds a JD from Stanford University.

Martin Silverstein

Dr. Martin Silverstein is Executive Vice President - Strategy of the Company. He will oversee Gilead's corporate development, commercial planning and alliance management functions. He previously held the role of Executive Vice President and Chief Strategy Officer at Anthem from April 2014 through December 2015. Prior to Anthem, Dr. Silverstein spent 28 years in roles of increasing responsibility at The Boston Consulting Group, including serving as Global Leader of its Health Care Practice, Senior Partner and Managing Director. He received a medical degree from Yale University, an MBA from Harvard Business School and a bachelor's degree from the University of Pennsylvania. He completed his internal medicine residency at Boston's Beth Israel Hospital and is board certified in Internal Medicine.

John Cogan

Dr. John F. Cogan,Jr., Ph.D., is Lead Independent Director of Gilead Sciences Inc. Dr. Cogan is currently the Leonard and Shirley Ely Senior Fellow at the Hoover Institution at Stanford University, where he has had a continuing appointment since 1980. Dr. Cogan’s current research is focused on U.S. budget and fiscal policy, healthcare and social security policy. Dr. Cogan has held a number of positions in the U.S. government, including Assistant Secretary for Policy in the U.S. Department of Labor and Associate Director and Deputy Director in the U.S. Office of Management and Budget. Dr. Cogan is a trustee of the Charles Schwab Family of Funds and a former director of Venture Lending and Leasing Funds.

Kevin Lofton

Mr. Kevin E. Lofton is an Independent Director of Gilead Sciences, Inc. He is currently, and has been since 2003, the Chief Executive Officer of Catholic Health Initiatives. Headquartered in Denver, the healthcare system has revenues of over $16 billion and operates the full continuum of services from hospitals to home health agencies throughout the nation. He previously served as Chief Executive Officer of two university hospitals, the University of Alabama at Birmingham Hospital and Howard University Hospital in Washington, D.C. In 2007, Mr. Lofton served as Chairman of the Board of the American Hospital Association, the nation’s largest hospital trade association. Mr. Lofton also serves on the Board of Directors of Rite Aid Corporation, Conifer Health Solutions LLC, a privately held revenue cycle management company in Dallas, and the Catholic Health Association.

John Madigan

Mr. John W. Madigan is an Independent Director of Gilead Sciences Inc. He is the retired Chairman and Chief Executive Officer of Tribune Company and a director and former Chairman of the Robert R. McCormick Foundation. Mr. Madigan is also a former member of the Defense Business Board of the Department of Defense, a former advisor to Madison Dearborn Partners and a director and former Chairman of The Chicago Council on Global Affairs. He previously served as a director of AT&T Wireless, Boise Cascade Holdings, L.L.C. and Morgan Stanley. He serves as a trustee of Northwestern University and Rush University Medical Center. Mr. Madigan is a member and former Chairman of The Commercial Club of Chicago and a director of New Schools for Chicago.

Nicholas Moore

Mr. Nicholas G. Moore is an Independent Director of Gilead Sciences Inc. Mr. Moore is the retired global Chairman of PricewaterhouseCoopers LLP, a professional services firm formed in July 1998 by the merger of Coopers & Lybrand and Price Waterhouse. Prior to the merger, Mr. Moore was elected Chairman and Chief Executive Officer of Coopers & Lybrand (U.S.) in 1994 and Coopers & Lybrand International in 1997. Mr. Moore is a director of Bechtel Group, Inc. He previously served as lead independent director of NetApp and director and chairman of the audit committee at Wells Fargo. He has also served as Chairman of the Board of Trustees of St. Mary’s College of California. Mr. Moore is an inactive member of the American Institute of Certified Public Accountants, the California Bar Association and the California and New York Society of Certified Public Accountants.

Richard Whitley

Dr. Richard James Whitley, M.D., is an Independent Director of Gilead Sciences Inc. He is a Distinguished Professor, Loeb Scholar Chair in Pediatrics; Co-Director, Division of Pediatric Infectious Diseases; Vice-Chair, Department of Pediatrics; Senior Scientist, Department of Gene Therapy; Associate Director for Drug Discovery and Development and Senior Leader, Pediatric Oncology Program, Comprehensive Cancer Center; Associate Director for Clinical Studies, Center for AIDS Research; and Co-Founder and Co-Director, Alabama Drug Discovery Alliance. Dr. Whitley has held responsibility for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, is a past President of the International Society of Antiviral Research and the Infectious Diseases Society of America and currently participates in the NIAID Recombinant DNA Advisory Council and the NIAID HIV Vaccine Data Safety and Management Board.

Gayle Wilson

Mrs. Gayle E. Wilson is an Independent Director of Gilead Sciences Inc. Mrs. Wilson served as California’s First Lady from 1991 to 1999. Mrs. Wilson is a member of the board of directors of the Ralph M. Parsons Foundation, a non-profit organization that provides grants for higher education, social impact, civic, cultural issues and health issues. She is also the Chair Emeritus of the Advisory Board of the California State Summer School for Math and Science and a member of the board of trustees of the California Institute of Technology.

Per Wold-Olsen

Mr. Per Wold-Olsen is an Independent Director of Gilead Sciences Inc. From 2005 to 2006, he served as President of the Human Health Intercontinental Division of Merck & Co., Inc., a global pharmaceutical company. From 1997 until 2005, he served as President of Human Health Europe, Middle East/Africa and Worldwide Human Health Marketing for Merck. Mr. Wold-Olsen is currently Chairman of the Board of GN Store Nord A/S. He also serves as a director of Exiqon A/S and Novo A/S. Mr. Wold-Olsen is Chairman of the Board of the Medicines for Malaria Venture, a non-profit initiative dedicated to the discovery, development and delivery of new medicines for the treatment of malaria.

Basic Compensation

Name Fiscal Year Total

John Martin

18,756,000

John Milligan

8,276,700

Robin Washington

5,557,230

Kevin Young

5,394,710

Norbert Bischofberger

6,953,070

Kathleen Watson

--

Gregg Alton

5,935,780

Martin Silverstein

--

John Cogan

454,702

Kevin Lofton

414,702

John Madigan

429,702

Nicholas Moore

434,702

Richard Whitley

429,702

Gayle Wilson

429,702

Per Wold-Olsen

414,702
As Of  30 Dec 2015

Options Compensation

Name Options Value

John Martin

6,717,868 324,682,100

John Milligan

2,009,008 104,162,400

Robin Washington

199,148 12,575,900

Kevin Young

325,000 17,346,800

Norbert Bischofberger

1,975,000 77,498,500

Kathleen Watson

0 0

Gregg Alton

572,000 36,592,200

Martin Silverstein

0 0

John Cogan

0 0

Kevin Lofton

0 0

John Madigan

0 0

Nicholas Moore

0 0

Richard Whitley

0 0

Gayle Wilson

0 0

Per Wold-Olsen

0 0